Cargando…

Pharmacological and Endoscopic Interventions for Prophylaxis of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis

BACKGROUND: Post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) represents the most common serious complication after endoscopic retrograde cholangiopancreatography (ERCP). Rectal non-steroidal anti-inflammatory drugs (NSAIDs) and pancreatic duct stenting (PDS) are the prophylacti...

Descripción completa

Detalles Bibliográficos
Autores principales: Palomera-Tejeda, Emmanuel, Shah, Mihir Prakash, Attar, Bashar M., Shah, Hassam, Sharma, Bharosa, Oleas, Roberto, Kotwal, Vikram, Gandhi, Seema, Mutneja, Hemant Raj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284647/
https://www.ncbi.nlm.nih.gov/pubmed/37351082
http://dx.doi.org/10.14740/gr1620
_version_ 1785061447629275136
author Palomera-Tejeda, Emmanuel
Shah, Mihir Prakash
Attar, Bashar M.
Shah, Hassam
Sharma, Bharosa
Oleas, Roberto
Kotwal, Vikram
Gandhi, Seema
Mutneja, Hemant Raj
author_facet Palomera-Tejeda, Emmanuel
Shah, Mihir Prakash
Attar, Bashar M.
Shah, Hassam
Sharma, Bharosa
Oleas, Roberto
Kotwal, Vikram
Gandhi, Seema
Mutneja, Hemant Raj
author_sort Palomera-Tejeda, Emmanuel
collection PubMed
description BACKGROUND: Post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) represents the most common serious complication after endoscopic retrograde cholangiopancreatography (ERCP). Rectal non-steroidal anti-inflammatory drugs (NSAIDs) and pancreatic duct stenting (PDS) are the prophylactic interventions with more evidence and efficacy; however, PEP still represents a significant source of morbidity, mortality, and economic burden. Chronic statin use has been proposed as a prophylactic method that could be cheap and relatively safe. However, the evidence is conflicting. We aimed to evaluate the impact of endoscopic and pharmacological interventions including chronic statin and aspirin use, on the development of PEP. METHODS: A retrospective cohort study evaluated consecutive patients undergoing ERCP at John H. Stroger, Jr. Hospital of Cook County in Chicago from January 2015 to March 2018. Univariate and multivariate analyses were performed using logistic regression. RESULTS: A total of 681 ERCPs were included in the study. Twelve (1.76%) developed PEP. Univariate, multivariate, and subgroup analyses did not show any association between chronic statin or aspirin use and PEP. PDS and rectal indomethacin were protective in patients undergoing pancreatic duct injection. Pancreatic duct injection, female sex, and younger age were associated with a higher risk. History of papillotomy was associated with lower risk only in the univariate analysis (all P values < 0.05). CONCLUSION: Chronic use of statins and aspirin appears to add no additional benefit to prevent ERCP pancreatitis. Rectal NSAIDs, and PDS after appropriate patient selection continue to be the main prophylactic measures. The lower incidence at our center compared with the reported data can be explained by the high rates of rectal indomethacin and PDS, the use of noninvasive diagnostic modalities for patient selection, and the expertise of the endoscopists.
format Online
Article
Text
id pubmed-10284647
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elmer Press
record_format MEDLINE/PubMed
spelling pubmed-102846472023-06-22 Pharmacological and Endoscopic Interventions for Prophylaxis of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis Palomera-Tejeda, Emmanuel Shah, Mihir Prakash Attar, Bashar M. Shah, Hassam Sharma, Bharosa Oleas, Roberto Kotwal, Vikram Gandhi, Seema Mutneja, Hemant Raj Gastroenterology Res Original Article BACKGROUND: Post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) represents the most common serious complication after endoscopic retrograde cholangiopancreatography (ERCP). Rectal non-steroidal anti-inflammatory drugs (NSAIDs) and pancreatic duct stenting (PDS) are the prophylactic interventions with more evidence and efficacy; however, PEP still represents a significant source of morbidity, mortality, and economic burden. Chronic statin use has been proposed as a prophylactic method that could be cheap and relatively safe. However, the evidence is conflicting. We aimed to evaluate the impact of endoscopic and pharmacological interventions including chronic statin and aspirin use, on the development of PEP. METHODS: A retrospective cohort study evaluated consecutive patients undergoing ERCP at John H. Stroger, Jr. Hospital of Cook County in Chicago from January 2015 to March 2018. Univariate and multivariate analyses were performed using logistic regression. RESULTS: A total of 681 ERCPs were included in the study. Twelve (1.76%) developed PEP. Univariate, multivariate, and subgroup analyses did not show any association between chronic statin or aspirin use and PEP. PDS and rectal indomethacin were protective in patients undergoing pancreatic duct injection. Pancreatic duct injection, female sex, and younger age were associated with a higher risk. History of papillotomy was associated with lower risk only in the univariate analysis (all P values < 0.05). CONCLUSION: Chronic use of statins and aspirin appears to add no additional benefit to prevent ERCP pancreatitis. Rectal NSAIDs, and PDS after appropriate patient selection continue to be the main prophylactic measures. The lower incidence at our center compared with the reported data can be explained by the high rates of rectal indomethacin and PDS, the use of noninvasive diagnostic modalities for patient selection, and the expertise of the endoscopists. Elmer Press 2023-06 2023-06-11 /pmc/articles/PMC10284647/ /pubmed/37351082 http://dx.doi.org/10.14740/gr1620 Text en Copyright 2023, Palomera-Tejeda et al. https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Palomera-Tejeda, Emmanuel
Shah, Mihir Prakash
Attar, Bashar M.
Shah, Hassam
Sharma, Bharosa
Oleas, Roberto
Kotwal, Vikram
Gandhi, Seema
Mutneja, Hemant Raj
Pharmacological and Endoscopic Interventions for Prophylaxis of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
title Pharmacological and Endoscopic Interventions for Prophylaxis of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
title_full Pharmacological and Endoscopic Interventions for Prophylaxis of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
title_fullStr Pharmacological and Endoscopic Interventions for Prophylaxis of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
title_full_unstemmed Pharmacological and Endoscopic Interventions for Prophylaxis of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
title_short Pharmacological and Endoscopic Interventions for Prophylaxis of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
title_sort pharmacological and endoscopic interventions for prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284647/
https://www.ncbi.nlm.nih.gov/pubmed/37351082
http://dx.doi.org/10.14740/gr1620
work_keys_str_mv AT palomeratejedaemmanuel pharmacologicalandendoscopicinterventionsforprophylaxisofpostendoscopicretrogradecholangiopancreatographypancreatitis
AT shahmihirprakash pharmacologicalandendoscopicinterventionsforprophylaxisofpostendoscopicretrogradecholangiopancreatographypancreatitis
AT attarbasharm pharmacologicalandendoscopicinterventionsforprophylaxisofpostendoscopicretrogradecholangiopancreatographypancreatitis
AT shahhassam pharmacologicalandendoscopicinterventionsforprophylaxisofpostendoscopicretrogradecholangiopancreatographypancreatitis
AT sharmabharosa pharmacologicalandendoscopicinterventionsforprophylaxisofpostendoscopicretrogradecholangiopancreatographypancreatitis
AT oleasroberto pharmacologicalandendoscopicinterventionsforprophylaxisofpostendoscopicretrogradecholangiopancreatographypancreatitis
AT kotwalvikram pharmacologicalandendoscopicinterventionsforprophylaxisofpostendoscopicretrogradecholangiopancreatographypancreatitis
AT gandhiseema pharmacologicalandendoscopicinterventionsforprophylaxisofpostendoscopicretrogradecholangiopancreatographypancreatitis
AT mutnejahemantraj pharmacologicalandendoscopicinterventionsforprophylaxisofpostendoscopicretrogradecholangiopancreatographypancreatitis